Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

The Lancet Oncology

Volumn 17, Issue 12, 2016, Pages 1653-1660

  Drilon, Alexander ^a   Rekhtman, Natasha ^a   Arcila, Maria ^a   Wang, Lu ^a   Ni, Andy ^a   Albano, Melanie ^a   Van Voorthuysen, Martine ^a   Somwar, Romel ^a   Smith, Roger S ^a   Montecalvo, Joseph ^a   Plodkowski, Andrew ^a   Ginsberg, Michelle S ^a   Riely, Gregory J ^a   Rudin, Charles M ^a   Ladanyi, Marc ^a   Kris, Mark G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CABOZANTINIB; ANILIDE; PROTEIN KINASE INHIBITOR; PROTEIN RET; PYRIDINE DERIVATIVE; RET PROTEIN, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT DISORDER; BRAIN METASTASIS; CANCER GROWTH; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRY SKIN; DYSGEUSIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOPIGMENTATION; HYPOTHYROIDISM; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; ORAL MUCOSITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROPERITONEAL HEMORRHAGE; TABLET FORMULATION; THROMBOCYTE COUNT; UNITED STATES; VOMITING; WEIGHT REDUCTION; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENE REARRANGEMENT; GENETICS; LUNG NEOPLASMS; MIDDLE AGED;

AGED; ANILIDES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; PYRIDINES;

EID: 85003533203     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30562-9     Document Type: Article

References (32)

1. 1 Solomon, BJ, Mok, T, Kim, DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
2. 2 Shaw, AT, Ou, SH, Bang, YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
3. 3 Lipson, D, Capelletti, M, Yelensky, R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18 (2012), 382–384.
4. 4 Suehara, Y, Arcila, M, Wang, L, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 18 (2012), 6599–6608.
5. 5 Drilon, A, Wang, L, Hasanovic, A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3 (2013), 630–635.
6. 6 Saito, M, Ishigame, T, Tsuta, K, Kumamoto, K, Imai, T, Kohno, T, A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. Carcinogenesis 35 (2014), 2452–2456.
7. 7 Kodama, T, Tsukaguchi, T, Satoh, Y, et al. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther 13 (2014), 2910–2918.
8. 8 Verbeek, HH, Alves, MM, de Groot, JW, et al. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab 96 (2011), E991–E995.
9. 9 Michels, S, Scheel, AH, Scheffler, M, et al. Clinicopathological Characteristics of RET rearranged lung cancer in European patients. J Thorac Oncol 11 (2016), 122–127.
10. 10 Wang, R, Hu, H, Pan, Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30 (2012), 4352–4359.
11. 11 Lee, SE, Lee, B, Hong, M, et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol 28 (2015), 468–479.
12. 12 Drilon, A, Wang, L, Arcila, ME, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res 21 (2015), 3631–3639.
13. 13 Yakes, FM, Chen, J, Tan, J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10 (2011), 2298–2308.
14. 14 Ju, YS, Lee, WC, Shin, JY, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22 (2012), 436–445.
15. 15 Kohno, T, Ichikawa, H, Totoki, Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18 (2012), 375–377.
16. 16 Takeuchi, K, Soda, M, Togashi, Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 18 (2012), 378–381.
17. 17 Simon, R, Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989), 1–10.
18. 18 Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
19. 19 Planchard, D, Kim, TM, Mazieres, J, et al. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol 17 (2016), 642–650.
20. 20 Kris, MG, Camidge, DR, Giaccone, G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 26 (2015), 1421–1427.
21. 21 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
22. 22 Hanna, N, Shepherd, FA, Fossella, FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004), 1589–1597.
23. 23 Kwak, EL, Bang, Y-J, Camidge, DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 (2010), 1693–1703.
24. 24 Mok, TS, Wu, YL, Thongprasert, S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009), 947–957.
25. 25 Nguyen, L, Benrimoh, N, Xie, Y, Offman, E, Lacy, S, Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs 27 (2016), 669–678.
26. 26 Mologni, L, Redaelli, S, Morandi, A, Plaza-Menacho, I, Gambacorti-Passerini, C, Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endorinol 377 (2013), 1–6.
27. 27 Planchard, D, Besse, B, Groen, HJ, et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17 (2016), 642–650.
28. 28 Subbiah, V, Berry, J, Roxas, M, et al. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer 89 (2015), 76–79.
29. 29 Lee, S-H, Lee, J-K, Ahn, M-J, et al. A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. Proc Am Soc Clin Oncol, 34(suppl), 2016 Abstr 9013.
30. 30 Seto, T, Yoh, K, Satouchi, M, et al. A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. Proc Am Soc Clin Oncol, 34(suppl), 2016 Abstr 9012.
31. 31 Gautschi, O, Wolf, J, Milia, J, et al. Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. Proc Am Soc Clin Oncol, 34(suppl), 2016 Abstr 9014.
32. 32 Oxnard, GR, Wilcox, KH, Gonen, M, Polotsky, M, Hirsch, BR, Schwartz, LH, Response rate as a regulatory end point in single-arm studies of advanced solid tumors. JAMA Oncol 2 (2016), 772–779.